Table 1.
Gastroprotective effect of the compounds 1-5, 7-16, 18-20 at 25 mg/kg on the HCl/EtOH induced gastric lesion model in mice.
| Compound | Gastroprotective effecta | |
|---|---|---|
| Lesion index | % Lesion reduction | |
| 1 | 12.3 ± 7.6** | 73.3 |
| 2 | 19.1 ± 8.3* | 58.5 |
| 3 | 12.6 ± 6.8** | 72.6 |
| 4 | 13.4 ± 6.8** | 70.9 |
| 5 | 34.3 ±12.0 | 25.4 |
| 7 | 21.2 ± 9.5* | 53.9 |
| 8 | 17.5 ± 9.9** | 62.0 |
| 9 | 18.4 ± 11.3** | 60.0 |
| 10 | 17.6 ± 7.8** | 61.7 |
| 11 | 12.9 ± 8.1** | 71.9 |
| 12 | 15.4 ± 8.8** | 66.5 |
| 13 | 15.8 ± 6.2** | 65.6 |
| 14 | 18.5 ± 11.8* | 59.8 |
| 15 | 12.1 ± 4.7** | 73.7 |
| 16 | 12.2 ± 6.9** | 73.5 |
| 18 | 23.2 ± 12.9* | 49.6 |
| 19 | 5.6 ± 3.2** | 87.8 |
| 20 | 14.3 ± 10.7* | 68.9 |
| Control | 46.0 ± 5.7 | 0 |
| Lansoprazole | 9.5 ± 2.5** | 79.3 |
a Gastroprotective effect shown as mean lesion index ± standard deviation (SD) and percent lesion reduction compared with untreated controls. b Reference drug: lansoprazole at 20 mg/kg. Significance set at *P < 0.05; **P < 0.01.